Council of Scientific and Industrial Research

Girish Kumar Jain

Man Mohan Singh

Anil Kumar Dwivedi

Naibedya Chattopadhyay

Atul Kumar

Suprabhat Ray

Sangita

Anil Kumar

Rakesh Maurya

Ritu Trivedi

Prem Prakash

Vishal Singh

Varsha Gupta

Divya Singh

Madhu Dikshit

Rabi Sankar Bhatta

Manoj Kumar Barthwal

Ankita Misra

Vivek Khanna

Puvvada Sri Ramanchandra Murthy

Manish Jain

Dinesh Kumar Dikshit

Tanveer Irshad Siddiqui

Lakshmi Manickavasagam

Amit Kumar

Atul Goel

Avinash Kumar

Vikram Khedgikar

Kamal Ram Arya

Jyoti Gautam

Sumit Chaurasia

Preeti Rawat

Kunal Sharan

Preety Dixit

Jawed Akhtar Siddiqui

Gaurav Swarnkar

Shelendra Pratap Singh

Geetanjali Mishra

Puvvada Sri Ramchandra Murthy

Wahajuddin

Jagdish Chandra Katiyar

Suman Gupta

Suman Tiwari

Abnish Kumar Gautam

Rashmi Pandey

Sheelendra Pratap Singh

The present invention relates to bioactive fractions and compounds fromfor the prevention or treatment of osteo-health related disorders. The present invention relates in the field of pharmaceutical composition that provides new plant extracts, their fractions and pure compound isolated from natural sources that are useful for the prevention and/or treatment of various medical indications associated with estrogen dependent or independent diseases or syndromes or disorders preferably in the prevention or treatment of estrogen dependent or independent diseases or syndromes or disorders caused in humans and animals, and achievement of peak bone mass during skeletal growth and health in humans and animals. Particularly the present invention further relates to the processes for the preparation of biologically active extracts, fractions, and isolation of pure compounds, fromplant from the family Fabaceae their pharmaceutically acceptable salts and compositions of the principal aspect of the present invention.

[object Object]

Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion. The present invention provides chiral (2S)-1-(4-methylphenylmethyl)-5-oxo-(3S)-{N-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)-{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively. The present invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors. The present invention provides a process for preparation of chiral carboxamides of formula 6 and 7 using the process which has advantage to avoid any racemization at the a-carboxylic center, during N-alkylation. The reagent LiHMDS is used at low temperatures to furnish methyl N-(p-methylphenylmethyl)1pyroglutamate in good chiral purity. 

Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl)-pyrrolidine as inhibitors of collagen induced platelet activation and adhesion

Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion The present invention provides chiral (2S)-1-(4-methyl-phenylmethyl)-5-oxo-(3S)&#x2014;{N-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)&#x2014;{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively. The present invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors. The present invention provides a process for preparation of chiral carboxamides of formula 6 and 7 using the process which has advantage to avoid any racemization at the a-carboxylic center, during N-alkylation. The reagent LiHMDS is used at low temperatures to furnish methyl N-(p methylphenylmethyl)lpyroglutamate in good chiral purity. 

Chiral 1-(4-methylphenylmethyl)-5-OXO-{N-[3-T-butoxycarbonyl-aminomethyl)]-piperidin-1-yl-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion

The present invention relates to novel substituted benzfurochromenes and related compounds having the general formula (I), salts and chiral, achiral derivatives thereof; wherein R, R, R, R, R, R, R, Rare independently selected from the groups consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted aroyl, optionally substituted acyloxy, optionally substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro but not limited to this; wherein RRor RRor RRmay be connected and form either a five membered ring or a six membered ring such as optionally substituted furan, optionally substituted dihydrofuran, optionally substituted pyran; or may be connected through a methylenedeoxy moiety; wherein X is selected from the units consisting of optionally a ketone group, optionally a methylene group, optionally substituted methylene group, optionally substituted alkene; wherein Y and Z is selected from the units consisting of CH, C&#x2014;OH, C-Me, C&#x2014;OMe with the proviso that bond between Y and Z is a single bond; Wherein Y and Z may be a carbon atom with the proviso that bond between Y and Z is a double bond. The compounds of the general formula is useful for the prevention and treatment of bone related disorders. 

Substituted benzfurochromenes and related compounds for the prevention and treatment of bone related disorders

The present invention provides a flavonol compound and a bioactive extract/fraction fromuseful for the management or prevention or treatment of bone disorders. Said extract/fraction comprising marker compounds of general formula 2, K058: R&#x2550;R&#x2550;OH K012: R&#x2550;R&#x2550;OH, 2,3 double bond K068: R&#x2550;R&#x2550;H KIOOi R&#x2550;OH, R&#x2550;H mula 2 Wherein the marker compounds K012, K058, K068, K1OO ranges 6.7-12%, 1.7-4.5%, 0.6-1.2%, 1.7-4.5% respectively in alcoholic extract and a process of extraction thereof. According to another aspect of the invention provides a pharmaceutical composition comprising the said compound. The present invention further provides a method of treating bone disorders by administering the pharmaceutical composition by oral, intravenous, subcutaneous, intra-peritoneal or intramuscular route. 

Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.

Mercaptophenyl naphthyl methane compounds and synthesis thereof

The present invention relates to compounds of the formula I in which substituents Rand Rare arranged in trans-configuration: wherein: wherein Y is chosen from NHR, NR, NHCOR, NHSOR, CONHR, CONR, CONR, COOH, COOR, SOR, SOR, SONHR, SONR, a C3-C7 heterocyclic ring, saturated or unsaturated, containing one or two heteroatoms independently selected from the group consisting of O, S and N, optionally being substituted with 1 to 3 substituents independently selected from the group comprising H, OH, halogen, nitro, cyano, SH, SR, trihalo-C1-C6-alkyl, C1-C6-alkyl and C1-C6-alkoxy, preferably NHR, NR, or a nitrogen heterocycle, wherein Ris as defined above, and the esters, ethers, and salts of the compounds of formula I, optionally along pharmaceutically acceptable excipients, a process for the preparation of the same, and a method of preventing and/or treating estrogen-related disease conditions in a subject using compounds of formula 1, or its salts, optionally along with pharmaceutically acceptable excipients.

(3R, 4R)-trans-3, 4-diarylchroman derivatives and a method for the prevention and/or treatment of estrogen dependent diseases

This invention is relation to a composition useful for the early diagnosis of visceral leishmaniasis comprising trypsinised and commassie brilliant blue stained Leishmania promastigotes and a protein stabilising solute in the ratios ranging from 5 million: 0.0001 mg to 100 million: 1.00 mg.

Composition useful for the early diagnosis of visceral leishmaniasis and a process for preparing the same

Growing community of inventors

Lucknow, India

Girish Kumar Jain